H.C. Wainwright raised the firm’s price target on AngioDynamics (ANGO) to $15 from $14 and keeps a Buy rating on the shares. The company reported a top- and bottom-line beat in fiscal Q2, the analyst tells investors in a research note.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ANGO:
- AngioDynamics price target raised to $15 from $12 at Canaccord
- AngioDynamics, Inc. Reports Growth in Med Tech Segment
- Morning Movers: AngioDynamics jumps following results and guidance raise
- AngioDynamics Hosts Virtual NanoKnife Investor Event
- AngioDynamics Reports Growth and Advances NanoKnife System